Bharat Biotech on Saturday announced safety and efficacy analysis data from phase III clinical trials of Covaxin.
The company said the efficacy analysis found that Covaxin is 77.8% effective against symptomatic Covid-19 through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.
The analysis also found that while Covaxin is 93.4 per cent effective against severe symptomatic Covid-19, it demonstrates an efficacy of 63.6% against asymptomatic Covid-19 and an efficacy of 65.2% against the SARS-CoV-2, B.1.617.2 Delta variant.
â€œThe successful safety and efficacy readouts of Covaxin as a result of conducting the largest ever Covid vaccine trials in India establishes the ability of India and developing world countries to focus on innovation and novel product development. We are proud to state that innovation from India will now be available to protect global populations,â€ said Dr Krishna Ella, chairman & managing director, Bharat Biotech.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.